📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Webster Financial Corporation operates as the bank holding company for Webster Bank, National Association that provides various financial products and services to businesses, individuals, and families in the United States. It operates through three segments: Commercial Banking, Healthcare Financial Services, and Consumer Banking. The company offers checking, savings, and money market accounts; time deposits; individual retirement account retirement savings; certificates of deposit; mortgages; home equity loans and lines of credit; business lines of credit; overdrafts; and term, commercial mortgages, student, PPA, SBA, and personal loans. It also provides commercial lending; financial planning, life and long-term insurance, personal retirement, and portfolio management solutions; employee retirement plans; credit cards; payroll services; automated clearing house payables and wires; bill pay, remote deposit capture, merchant, and lockbox services; treasury management and investment services; private banking services; wealth management services; and online and mobile banking services. Webster Financial Corporation was founded in 1870 and is headquartered in Stamford, Connecticut.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q1 2025

Confident Specific

Management used specific numbers (EPS $1.30, ROA 1.15%, NIM +4bp, 30% recession probability, $20M reserve build) and repeatedly stated they are on track to meet full-year guidance, while acknowledging macroeconomic uncertainty but insisting on stable underlying trends.

Q2 2025

Confident Specific

Management used precise metrics (ROTCE 18%, ROA 1.3%, loan growth 1.2%) and reaffirmed full-year NII guidance of $2.47B-$2.5B. They highlighted concrete catalysts like HSA reform and the Marathon JV, and explicitly stated credit inflection is materializing.

Q3 2025

Confident Specific

Management uses strong positive language: 'very strong results' (ROTCE 18%, ROA 1.3%), 'growth in both loans and deposits of over 2%', 'revenue grew 2.3%'. They provide specific forward guidance on NII, NIM, and fees, and defend credit quality with quantified improvements in criticized loans. No hedging or defensive language detected.

Q4 2025 latest

Confident Specific

Management used emphatic positive language such as excelled, on our front foot, record year, and provided precise metrics (17% ROTCE, 1.2% ROA, EPS up 10%, loans up 8%, deposits up 6%) throughout the call, reinforcing execution success.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. Webster delivered a record 2025 with double-digit ROTCE, tangible book growth, and consistent credit improvement. The 2026 guidance is moderate but credible, underpinned by durable growth engines (HSA, Ametros, diversified loan origination) and a clear capital return strategy. Key watch items next quarter: the pace of HSA account openings from ACA Bronze enrollees, credit migration in the residual office/healthcare portfolios, and any update on the CET1 target reduction. The Marathon JV contribution remains small but could be an upside driver if sponsor activity picks up.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Webster Financial posts 17% ROTCE, 1.2% ROA; loans +8%, deposits +6% in 2025

Revenue & Profitability

For full year 2025, Webster reported earnings per share up 10% year-over-year, with adjusted net income slightly higher in Q4 versus the prior quarter. Net interest margin (NIM) exited December at 3.35%, and the company guided 2026 revenue of approximately $3 billion (GAAP), with net interest income of $2.57 billion to $2.63 billion and fees of $390 million to $410 million. Tangible book value per share rose to $37.20 from $36.42 in the prior quarter. Net charge-offs were 35 basis points in Q4.

Outlook

Management sees positive momentum from macroeconomic and regulatory tailwinds, with a supportive backdrop for asset quality. The healthcare policy environment in Washington could expand HSA eligibility to more Americans, potentially driving $1-2.5 billion in incremental HSA deposits over five years. However, deposit competition remains strong across commercial and consumer categories, and loan spreads have tightened 30-50 basis points over the past 18 months.

Growth Drivers

Key growth levers include HSA Bank's Bronze plan opportunity (expected $50-100 million in incremental deposits in 2026), sustained mid-20% deposit growth at Ametros, and diversified commercial loan growth across C&I and CRE. The Marathon joint venture may add upsize potential in sponsor lending. Newly acquired SecureSave (emergency savings accounts) offers another distribution channel. Loan growth guidance for 2026 is 5-7%, with deposit growth of 4-6%.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Net interest margin is expected to remain around 3.35% for full year 2026, with a slight uptick in Q1 due to seasonality. Deposit costs fell 11 basis points in Q4 to an average of 1.91% at period end. Management assumes a 30% deposit beta through the current rate cycle. Expenses for 2026 are guided at $1.46-1.48 billion, with Q1 costs a few percentage points higher due to payroll taxes, annual merit, and benefits.

Key Risks

Risks include credit performance in the office ($720 million) and healthcare services ($400 million) portfolios, which remain sticky non-performing assets, though management says they are ring-fenced and reserved. Macroeconomic uncertainty and rapid rate cuts could pressure NIM. HSA growth depends on legislative changes that are uncertain. The company also flagged higher-than-expected payoff activity and persistent competition as potential headwinds.

Generated by AI · Q4 2025 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q4 2025 Q4 2025 2026-01-23

Delivered record 2025 results with double-digit EPS and tangible book value growth, strong loan and deposit expansion, and robust capital returns. 2026 guidance calls for continued growth, stable NIM, and further HSA-driven deposit gains, with risk well-managed and capital ratios above targets.

Q3 2025 Q3 2025 2025-10-17

Q3 delivered strong profitability with 18% ROTCE, 2%+ loan and deposit growth, and higher revenue. Asset quality improved, capital ratios remain robust, and strategic initiatives like the HSA Bank expansion and private credit JV are progressing well.

Q2 2025 Q2 2025 2025-07-17

Q2 saw strong growth in loans, deposits, and revenue, with improved asset quality and robust capital. HSA Bank's addressable market is expanding, and the Marathon JV is set to drive future fee income. NIM is expected to end 2025 between 3.35% and 3.40%.

Q1 2025 Q1 2025 2025-04-24

Solid Q1 results featured strong deposit and loan growth, stable NIM, and robust capital. Credit quality challenges were concentrated in healthcare and office CRE, but overall asset quality trends are stabilizing. Full-year guidance and capital return plans remain intact.

Q4 2024 Q4 2024 2025-01-17

Delivered strong Q4 and full-year results with robust loan and deposit growth, improved efficiency, and a solid capital position. Strategic actions included reducing CRE exposure, acquiring Ametros, and investing in technology. 2025 guidance calls for 4%-5% growth in loans and deposits, stable margins, and continued expense discipline.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.